2014 (Millions of yen) Pension and lump-sum payment Other Japan Overseas Total Present value of defined benefit obligations ¥ 117,862 ¥ 57,182 ¥ 175,044 ¥2,959 Fair value of plan assets (111,719) (39,904) (151,623) — Funded status 6,143 17,278 23,421 2,959 Effect of the asset ceiling — 220 220 — Net defined benefit liability (asset) ¥ 6,143 ¥ 17,498 ¥ 23,641 ¥2,959 Amounts in the consolidated statements of financial position Assets (other non-current assets) ¥ (583) ¥ — ¥ (583) ¥ — Liabilities (retirement benefit liabilities) 6,726 17,498 24,224 2,959 (Millions of yen) Pension and lump-sum payment Other Japan Overseas Total Balance at 1 April 2012 ¥106,195 ¥29,615 ¥135,810 ¥1,987 Current service cost 4,289 754 5,043 246 Interest cost 1,999 1,461 3,460 52 Remeasurements of defined benefit obligations – actuarial losses arising from changes in demographic assumptions — 518 518 — – actuarial losses arising from changes in financial assumptions 11,696 7,886 19,582 366 – other 1,247 107 1,353 (29) Past service cost, and gains and losses arising from settlements — (95) (95) 9 Contributions to the plan by plan participants — 381 381 — Payments from the plan (6,160) (1,040) (7,199) (90) Effect of changes in foreign exchange rates — 4,317 4,317 291 Balance at 31 March 2013 119,266 43,905 163,171 2,832 Current service cost 5,009 1,568 6,577 454 Interest cost 1,213 1,794 3,006 73 Remeasurements of defined benefit obligations – actuarial losses arising from changes in demographic assumptions — 0 0 3 – actuarial (gains)/losses arising from changes in financial assumptions (1,013) 4,354 3,341 (331) – other (154) 330 176 (160) Past service cost, and gains and losses arising from settlements — (29) (29) — Contributions to the plan by plan participants — 500 500 — Payments from the plan (6,458) (2,951) (9,409) (140) Effect of changes in foreign exchange rates — 7,711 7,711 228 Balance at 31 March 2014 ¥117,862 ¥57,182 ¥175,044 ¥2,959 The movement of the present value of defined benefit obligations is as follows: Annual Report 2014 _  Astellas Pharma Inc.  135 Financial Section